Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Study Identifier
190342-024T
CT.gov Identifier
NCT00651612
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
  • Concurrent brimonidine 0.2% and 0.5% timolol
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of ocular hypertension or glaucoma * Patient requires IOP-lowering therapy in both eyes
    Exclusion Criteria:
    * Uncontrolled medical conditions * Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy

    Protocol Summary

    This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients

    Study Locations

    Location
    Status
    Location
    Newport Beach, California, United States
    Status
    Not applicable